Drugs / AGN-190584
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT05393089 | Jun 2022 → Apr 2023 | presbyopia | Allergan | Withdrawn | No outcome recorded |
| Phase 2 | NCT02780115 | May 2016 → Oct 2017 | presbyopia | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02595528 | Apr 2016 → Oct 2017 | presbyopia | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT02197806 | Jul → Oct 2014 | presbyopia | Allergan | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04837482 | May → Dec 2021 | presbyopia | AbbVie | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05624320 | Dec 2022 → May 2023 | presbyopia | Gordon Schanzlin New Vision | Withdrawn | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-05 | AbbVie | Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia) abbvie.com ↗ |
| 2021-12-09 | AbbVie | VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available abbvie.com ↗ |
| 2021-10-29 | AbbVie | U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) abbvie.com ↗ |
| 2021-10-26 | AbbVie | Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia abbvie.com ↗ |
| 2021-07-25 | AbbVie | New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition abbvie.com ↗ |
| 2021-02-25 | AbbVie | Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia abbvie.com ↗ |
| 2020-10-28 | AbbVie | Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia abbvie.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-190584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624320 ↗ |
| Known as | pilocarpine | “AGN-190584 is an investigational formulation of pilocarpine for treating symptoms associated with presbyopia as a topical, once-daily eyedrop delivered by a proprietary vehicle.” NCT04837482 ↗ |
| Route | Other | “1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.” NCT02197806 ↗ |